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CTLA-4 is a key immune checkpoint in maintaining self-tolerance, which can be co-opted by cancer to evade
immune attack. In Science, Kuehn et al. (2014) describe clinical manifestations from inherited heterozygous
CTLA4 mutations, and some are reminiscent of immune-related consequences from anti-CTLA-4 cancer
therapy.Cytotoxic T lymphocyte antigen 4 (CTLA-
4) is an essential negative regulator of
peripheral T cell function. CTLA-4 and
the T cell costimulatory receptor CD28
share the ligands CD80 and CD86, but
CTLA-4 is their high-affinity receptor.
CTLA-4 is expressed inducibly on CD4+
Foxp3 conventional T (Tconv) cells after
activation and constitutively on CD4+
Foxp3+ regulatory T (Treg) cells. The crit-
ical inhibitory function of CTLA-4 has
been revealed by the rapidly fatal in-
flammatory phenotype of CTLA-4-null
(Ctla4/) mice, which spontaneously
develop massive T cell expansion with
multiorgan lymphocytic infiltration and
tissue destruction (Tivol et al., 1995). The
similarity of this phenotype to systemic
autoimmune disease has catalyzed
studies investigating the role of CTLA-4
in T cell tolerance and autoimmunity.
CTLA-4 can act on Tconv and Treg cells
and is a mediator of Treg cell suppressive
function.
Although the crucial roles for CTLA-4 in
inhibiting T cell responses and mediating
peripheral T cell tolerance are firmly es-
tablished, there remain many questions
about the mechanisms by which CTLA-4
exerts its critical immunoregulatory func-
tions. Data support both cell-intrinsic
and cell-extrinsic mechanisms. Antibody-
mediated ligation of CTLA-4 (which trig-
gers CTLA-4 crosslinking) inhibits CD3-
and CD28-mediated T cell stimulation,
supporting cell-intrinsic inhibitory effects.
The CTLA-4 cytoplasmic tail has a poten-
tially inhibitory motif, which can negate
signals from the T cell receptor (TCR)
and from CD28 by recruiting phospha-
tases. Recent work has shown that kinase
PKC-h constitutively binds to the CTLA-4682 Immunity 41, November 20, 2014 ª2014cytoplasmic domain in Treg cells and that
this interaction is an importantmediator of
CTLA-4 function in these cells (Kong et al.,
2014). However, other data support cell-
extrinsic mechanisms of CTLA-4 function.
CTLA-4 could exert cell-extrinsic effects
by attenuating CD80 and/or CD86 ex-
pression on antigen-presenting cells
(APCs), either indirectly by causing their
downregulation or directly by removing
them from APCs by transendocytosis,
thereby reducing their availability for
CD28 engagement and costimulation.
In addition, CTLA-4 could reverse signal
into APCs through CD80 and/or CD86
and induce the immunosuppressive
enzyme indoleamine 2,3 dioxygenase.
The seminal demonstration that CTLA-
4 blockade could reverse immunosup-
pression in the tumor microenvironment
andmediate the regression of established
cancers in murine models (Leach et al.,
1996) led to the clinical development of
antibodies blocking CTLA-4 in patients
with advanced malignancies. In 2011,
the CTLA-4 monoclonal antibody ipilimu-
mab became a standard therapy for
patients with advanced metastatic mela-
noma on the basis of phase 3 clinical trial
results showing improved overall survival
(Hodi et al., 2010). This established
a new treatment paradigm for cancer,
namely, blocking immune checkpoints
to ‘‘release the brakes’’ on antitumor
immunity. However, anti-CTLA-4 therapy
was accompanied by autoimmune mani-
festations that were not predicted by
preclinical models and that occurred in
patients without a prior medical history
of autoimmunity.
A recent report describes severe
immune dysregulation in individualsElsevier Inc.harboring heterozygous CTLA4 germline
mutations associated with decreased
CTLA-4 expression in immune cells
(Kuehn et al., 2014). Seven CTLA4 hetero-
zygotes from four unrelated families
were studied intensively. Although one
77-year-old individual remained asymp-
tomatic, six others developed severe
immune dysregulation at ages ranging
from 2 to 40 years. Clinical manifesta-
tions—including pulmonary infiltrates,
gut inflammation, cytopenias, and hypo-
gammaglobulinemia (six of six patients);
autoantibodies (five of six); and focal
brain inflammation (three of six)—were
cumulative and progressive. Reminiscent
of biopsies of inflamed organs in patients
receiving anti-CTLA-4, biopsies of
affected organs demonstrated mixed
lymphoid infiltrates. CTLA-4 mRNA and
protein levels in effector and Treg cells
were reduced. Wide-ranging effects
on circulating lymphocytes, including
effector T cells (hyperproliferative CD4+
and CD8+ cells; see Figure 1), Treg cells
(decreased Foxp3 and CD25 expres-
sion and decreased suppression of CD4+
T cell proliferation), and B cells (decreased
mature CD20+ cells and increased ‘‘ex-
hausted’’ CD21lo cells), were reported.
Another report of heterozygous CTLA4
mutations in six different families de-
scribes 14 affected individuals with similar
clinical findings and eight asymptomatic
carriers who nevertheless harbored T cell
phenotypic and functional abnormalities
(Schubert et al., 2014). Similar to mouse
data, these studies of individuals with het-
erozygous CTLA4 germline mutations
support both cell-intrinsic and cell-
extrinsic functions for CTLA-4. However,
although heterozygous CTLA-4 loss in
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Figure 1. Development of Autoimmunity in Patients with CTLA-4 Haploinsufficiency
In naive T lymphocytes from healthyCTLA4+/+ individuals, TCR signaling in response to cognate antigen is
accompanied by CD28 costimulation, resulting in the rapid induction of inhibitory CTLA-4 coreceptors on
the cell surface. CTLA-4 has a higher affinity for the ligands CD80 and CD86 than for CD28. Therefore, a
switch to negative signaling occurs to inhibit T cell activation and appropriately conclude the immune
response. In contrast, CTLA-4-haploinsufficient patients express reduced levels of CTLA-4 on activated
T effector cells. This alters the balance between stimulatory CD28 and inhibitory CTLA-4 signals, sustain-
ing the activation and proliferation of antigen-specific T cells and leading to autoimmunity. pMHC, peptide
major histocompatibility complex.
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Previewsmice can lead to increased Treg cell
frequencies, it does not produce the se-
vere inflammatory manifestations seen in
Ctla4/mice or in humans with heterozy-
gous CTLA4mutations.
The report by Kuehn et al. describing
the consequences of decreased CTLA-4
expression bears notable similarities
to, as well as distinctions from, reports
of inflammatory disorders associated
with anti-CTLA-4 cancer therapy. Among
540 melanoma patients receiving inter-
mittent CTLA-4 blockade with ipilimu-
mab, approximately 60% experienced
immune-related adverse events, and
11% had severe symptoms, the most
common of which were dermatologic
(rash and vitiligo), gastrointestinal (entero-
colitis), and endocrine (hypothyroidism
and hypophysitis) (Hodi et al., 2010).
Less common inflammatory events
included hepatitis, uveitis, neurologic dis-
orders, and pneumonitis (Attia et al.,
2005). Although most immune-related
toxicities were readily managed with
immunosuppressive drugs, some were
fatal. Biopsies of inflamed organs demon-
strated mixed CD4+ and CD8+ T cell infil-
trates. Increased serum titers of autoanti-bodies observed in some patients were
directed against thyroid tissue, acetylcho-
line receptor, pituitary gland, and other
targets. A significant correlation between
severe immune-related toxicities and
major tumor regressions was described
(Attia et al., 2005), suggesting common
biological mechanisms and highlighting
the precarious balance between self-
tolerance and autoimmunity in malignant
and normal tissues.
Descriptions of asymptomatic adults
with heterozygous CTLA4 deficiencies
(Kuehn et al., 2014, Schubert et al.,
2014), and widely varying ages of onset
among symptomatic individuals, imply
that additional interacting factors are
required for surmounting an autoimmune
threshold. These factors might include
other genetic or epigenetic events and
environmental influences (microbial or
other). The variable penetrance of genetic
CTLA4 disorders mirrors clinical experi-
ence with CTLA-4 blockade. Immune-
related toxicities can occur after the first
drug dose or much later during treatment,
can be mild or severe, and can respond
promptly to corticosteroids or require
additional immunosuppressants. Expo-Immunity 41, Nsure of some frequently affected organs
(skin and gut) to the microbiome has
suggested that this environmental factor
might contribute to generating auto-
immunity in patients receiving ipilimumab.
Interestingly, Ctla4/ mice die within
2 weeks of age even when they are reder-
ived into germ-free environments, sug-
gesting the importance of self-antigens
in driving the inflammatory phenotype.
It is currently unknown how the degree,
timing, and cell-type specificity of CTLA-4
deficiency might influence autoimmune
consequences. Foxp3-specific CTLA-4
deficiency in mice results in a fatal immu-
nopathology that is delayed in onset and
more restricted than that in Ctla4/
mice (Wing et al., 2008). The rapidly
lethal phenotype of Ctla4/ mice con-
trasts sharply with murine heterozygous
models and cancer-treatment models
using short-lived anti-murine CTLA-4
antibodies in wild-type animals. Recent
reports suggest that some of the thera-
peutic effects of anti-CTLA-4 are achieved
through depletion of tumor-infiltrating
Treg cells (Selby et al., 2013). These find-
ings might explain differences observed
between genetic and antibody-mediated
CTLA-4 deficiency. Furthermore, severe
immune dysfunction in human heterozy-
gotes with partial but chronically reduced
CTLA-4 expression can be contrasted to
the more limited, organ-specific immune
reactivity observed in some cancer pa-
tients receiving anti-CTLA-4 intermittently.
Collectively, these findings imply that
exploring different dosing schedules of
anti-CTLA-4 might effectively uncouple
antitumor immunity from autoimmunity in
patients with cancer.
Kuehn et al. found CTLA-4 expression
on B cells and an increased frequency
of CD21lo B cells in patients with hetero-
zygous CTLA4 mutations. CTLA-4 can
be expressed on B cells, but whether it
exerts direct effects on B cells is unclear.
Ctla4/ mice have increased antibody
levels, which might reflect CTLA-4 func-
tion in T or B cells. Foxp3-specific
CTLA-4 deficiency in mice leads to mark-
edly increased autoantibody production,
pointing to an essential role for CTLA-4
on Treg cells in regulating B cell re-
sponses. Aberrant anti-self immunoglob-
ulin responses, particularly responses
against neuronal tissues, are a hallmark
of paraneoplastic syndromes and are
thought to represent cross-reactivitiesovember 20, 2014 ª2014 Elsevier Inc. 683
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Previewsagainst determinants shared by tumor
and normal cells (Steinman 2014). Inter-
estingly, endocrine gland abnormalities
characteristic of anti-CTLA-4 therapy
might represent the emergence of pre-
viously subclinical paraneoplastic phe-
nomena targeting neural-crest-derived
hormone-producing cells.
As Kuehn et al. have shown, a delicate
balance exists between self-tolerance
and autoimmunity that is governed, at
least in part, by quantitative variations in
CTLA-4 expression. As predicted by pre-
clinical models, the complex interplay
between genetics and the environment
might determine the evolution of distinct
phenotypes associated with CTLA-4
deficits, or conversely, the maintenance
of an asymptomatic state. A deeper un-
derstanding of these interacting factors
will be needed for the optimal develop-
ment of drugs blocking CTLA-4 and other
immune checkpoints (such drugs are
showing promise in the clinic). Tumors
masquerading as self might then be re-684 Immunity 41, November 20, 2014 ª2014vealed as foreign to the immune system,
resulting in tumor elimination without
incurring anti-self consequences. Thus,
as revealed by both genetic and drug-
induced CTLA-4 imbalances, the immune
system appears to have been fine-tuned
to live life on the edge.ACKNOWLEDGMENTS
S.L.T. is a recipient of research support from the
Bristol Myers Squibb Corporation, which manu-
factures ipilumab, an anti-CTLA-4 monoclonal
antibody. This work was supported in part by NIH
P01 AI39671 to A.H.S.REFERENCES
Attia, P., Phan, G.Q., Maker, A.V., Robinson, M.R.,
Quezado, M.M., Yang, J.C., Sherry, R.M., Topa-
lian, S.L., Kammula, U.S., Royal, R.E., et al.
(2005). J. Clin. Oncol. 23, 6043–6053.
Hodi, F.S., O’Day, S.J., McDermott, D.F.,
Weber, R.W., Sosman, J.A., Haanen, J.B., Gon-
zalez, R., Robert, C., Schadendorf, D., Hassel,
J.C., et al. (2010). N. Engl. J. Med. 363,
711–723.Elsevier Inc.Kong, K.F., Fu, G., Zhang, Y., Yokosuka, T., Casas,
J., Canonigo-Balancio, A.J., Becart, S., Kim, G.,
Yates, J.R., 3rd, Kronenberg, M., et al. (2014).
Nat. Immunol. 15, 465–472.
Kuehn, H.S., Ouyang, W., Lo, B., Deenick, E.K.,
Niemela, J.E., Avery, D.T., Schickel, J.-N., Tran,
D.Q., Stoddard, J., Zhang, Y., et al. (2014). Science
345, 1623–1627.
Leach, D.R., Krummel, M.F., and Allison, J.P.
(1996). Science 271, 1734–1736.
Schubert, D., Bode, C., Kenefeck, R., Hou, T.Z.,
Wing, J.B., Kennedy, A., Bulashevska, A., Pe-
tersen, B.S., Scha¨ffer, A.A., Gru¨ning, B.A., et al.
(2014). Nat. Med. http://dx.doi.org/10.1038/nm.
3746.
Selby, M.J., Engelhardt, J.J., Quigley, M., Henning,
K.A., Chen, T., Srinivasan, M., and Korman, A.J.
(2013). Cancer Immunol. Res. 1, 32–42.
Steinman, L. (2014). Eur. J. Immunol. http://dx.doi.
org/10.1002/eji.201445191.
Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch,
W.P., Bluestone, J.A., and Sharpe, A.H. (1995).
Immunity 3, 541–547.
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi,
T., Miyara, M., Fehervari, Z., Nomura, T., and Saka-
guchi, S. (2008). Science 322, 271–275.
